Apolipoprotein E (APOE) and warfarin dosing in an Italian population [1]

European Journal of Clinical Pharmacology

Volumn 61, Issue 10, 2005, Pages 781-783

  Kohnke, Hugo ^a   Scordo, Maria Gabriella ^a   Pengo, Vittorio ^b   Padrini, Roberto ^b   Wadelius, Mia ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Clinical and Experimental Medicine and Pharmacology ^*  (Italy)

Author keywords

APOE; Apolipoprotein E; CYP2C9; Pharmacogenetics; Vitamin K; Warfarin

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450 2C9; WARFARIN;

ALLELE; ANALYSIS OF VARIANCE; DRUG ACTIVITY; DRUG DOSE REGIMEN; GENOTYPE; HUMAN; ITALY; LETTER; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ANTICOAGULANTS; APOLIPOPROTEINS E; GENE FREQUENCY; GENOTYPE; HUMANS; ITALY; PHENOTYPE; WARFARIN;

EID: 27944509205     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0982-x     Document Type: Letter

References (17)

1. Landefeld C, Beyth R (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 95:315-328, DOI:10.1016/0002-9343(93)10285-w
2. Bell RG, Sadowski JA, Matschiner JT (1972) Mechanism of action of warfarin. Warfarin and metabolism of vitamin K1. Biochemistry 11:1959-1961
3. Berkner KL, Runge KW (2004) The physiology of vitamin K nutriture and vitamin K-dependent protein function in atherosclerosis. J Thromb Haemost 2:2118-2132
4. Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H (1999) Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 81:396-399
5. Wells P, Holbrook A, Crowther N, Hirsh J (1994) Interactions of warfarin with drugs and food. Ann Intern Med 121:676-683
6. Kohlmeier M, Salomon A, Saupe J, Shearer MJ (1996) Transport of vitamin K to bone in humans. J Nutr 126:1192S-1196S
7. Rocchi A, Pellegrini S, Siciliano G, Murri L (2003) Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 61:1-24, DOI.org/10.1016/s.361-9230(03)00067-4
8. Weintraub MS, Eisenberg S, Breslow JL (1987) Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest 80:1571-1577
9. Saupe J, Shearer MJ, Kohlmeier M (1993) Phylloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr 58:204-208
10. Kohlmeier M, Saupe J, Drossel HJ, Shearer MJ (1995) Variation of phylloquinone (vitamin K1) concentrations in hemodialysis patients. Thromb Haemost 74:1252-1254
11. O'Reilly RA (1974) Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 16:348-354
12. Kaminsky L, Zhang Z (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
13. Daly AK, King BP (2003) Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13:247-252
14. Kohnke H, Sörlin K, Granath G, Wadelius M (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 61:381-388, DOI:10.1007/s00228-005-0936-3
15. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710, DOI:10.1067/mcp.2002.129321
16. Ewbank DC (2004) The APOE gene and differences in life expectancy in Europe. J Gerontol A Biol Sci Med Sci 59:16-20
17. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L (1993) Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem 39:2125-2129